Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors

The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer
• Disease progression following non-steroidal aromatase inhibitor treatment

Exclusion Criteria:

• Known symptomatic brain metastasis
• Medical condition requiring chronic steroids
• History of Type 1 or 2 Diabetes
• Uncontrolled or significant cardiovascular (CV) disease
• Concomitant second malignancies